Last reviewed · How we verify
ASLAN003
ASLAN003 is a monoclonal antibody targeting the PD-1 receptor.
ASLAN003 is a monoclonal antibody targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | ASLAN003 |
|---|---|
| Also known as | LAS186323 |
| Sponsor | ASLAN Pharmaceuticals |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, ASLAN003 prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (PHASE2)
- A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia (PHASE2)
- Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003 (PHASE1)
- A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASLAN003 CI brief — competitive landscape report
- ASLAN003 updates RSS · CI watch RSS
- ASLAN Pharmaceuticals portfolio CI